



Prof. Magnus Ingelman-Sundberg, PhD; BSc.Med

Karolinska Institutet
Department of Physiology and Pharmacology (FYFA), C3
Stockholm
Sweden

Professor of Molecular Toxicology since 1996 and research group leader in Pharmacogenetics at the Department of Physiology and Pharmacology, Karolinska Institutet since 2006.

Academic honors, awards and prizes

- More than 420 original papers, 22 000 citations (32 000 in Google Scholar) and an h-factor of 82 (ISI) or 94 (Google Scholar). Member of *The Nobel Assembly at Karolinska Institutet* since 2008 and member of *Faculty of 1000 Biology* since 2006. Member of Editorial Advisory Boards of e.g. *Trends in Pharmacological Sciences*, *Pharmacogenetics and Genomics*, *Pharmacogenomics*, *Drug Metabolism Reviews*, *Drug Metabolism and Disposition*. Chairman of the Microsomes and Drug Oxidation International Advisory Committee, mdo.ki.se.
- Ranked as the 3rd „highest impact“ researcher of 4,000 in the field of drug metabolism (cytochrome.net) and one of the world's most cited authors within the category Pharmacology (<http://isihighlycited.com/>). Recently categorized by Thomson Reuters as one of the World's Most Influential Scientific Minds ([http:// sciencewatch.com/sites/sw/files/sw-article/media/worlds-most-influential-scientific-minds-2014.pdf](http://sciencewatch.com/sites/sw/files/sw-article/media/worlds-most-influential-scientific-minds-2014.pdf)) based on recent (2002-2012) citations.
- Main supervisor to a PhD degree for 29 postgraduate students, postdoctoral training for 25 PhDs. The research group ranked as outstanding in Karolinska Institutet's External Research Assessment (ERA) in 2010.
- Awards include The Svedberg Price, The Swedish Society for Biochemistry and Molecular Biology 1989; Honorary member of The American Society for Biochemistry and Molecular Biology 1990; The Gerhard B Zbinden Lecture Award, EUROTOX 1996; The ISSX European Scientific Achievement Award 2003; The Bengt Danielsson Prize, The Swedish Academy of Pharmaceutical Sciences 2008; The John G Warner Pfizer Lectureship in Pharmaceutical Sciences, University of Michigan, USA 2011.
- Interview with Magnus Ingelman-Sundberg. *Trends Pharmacol Sci.* 2015;36:65-7.

Selected references:

1. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. *N Engl J Med.* 2008;358:637-9.
2. Ivanov M, Kals M, Kacevska M, Metspalu A, Ingelman-Sundberg M, Milani L. In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. *Nucleic Acids Res.* 2013, 41(6):e72. doi: 10.1093/nar/gks1467.
3. Ivanov M, Kals M, Kacevska M, Barragan I, Kasuga K, Rane A, Metspalu A, Milani L, Ingelman-Sundberg M. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. *Genome Biol.* 2013 Aug 19;14(8):R83.
4. Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. *Mol Psychiatry.* 2014 Jun;19(6):733-41
5. Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. *Trends Pharmacol Sci.* 2014 Aug;35(8):384-96